Under a pharmacare plan, a single bargaining agent negotiates for lower prices from drug companies.
Pharmaceutical and insurance industries that could lose profit through lower drug prices are not happy that a pharmacare bill is planned for fall. They are speaking out and mobilizing their allies.
Health Canada’s new drug licensing proposal contains no mechanism for making fast-tracked medicines affordable.
THE CANADIAN PRESS/Ryan Remiorz
The federal government’s proposed Agile Licensing drug approval regulations mean Canada will have less information about the risks of new medicines, and higher costs.
People for millennia have used what grows around them as medicine.
LorenzoT81/iStock via Getty Images Plus
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
Research confirms the adverse effects of social media on mental health.
Some commercial products and practices are directly linked to avoidable ill health, planetary damage, and social and health inequity. Large transnational corporations are especially to blame.
The pharma industry warned that if proposed new prescription price guidelines go ahead, drug launches would be delayed and ‘Canadian patients will be deprived of potentially life-saving new medicines.’
The pharma industry claims lower prescription drug prices will mean less access to new medication for Canadians. It’s an old threat that pits profits against patients’ rights to affordable drugs.
Lecanemab is an antibody that attaches to beta-amyloid proteins accumulated in the brain and allows the immune system to get rid of them.
An 18-month treatment with lecanemab slows functional and cognitive loss by 27 per cent in people with mild Alzheimer’s disease. But this is only the first step towards a real cure.
Global Justice campaigners in London stand by fake coffins to highlight global COVID-19 deaths. If pharma companies waived intellectual property rights, it would be easier for low- and middle-income countries to access COVID-19 vaccines.
(AP Photo/Alastair Grant)
Waiving patent rights on COVID-19 vaccines and drugs is still crucial to ensure access globally, but the waiver on the table at the June World Trade Organization meeting doesn’t do the job.
Changes to the Patented Medicine Prices Review Board regulations, which are intended to help lower drug costs in Canada, were originally scheduled to take effect in July 2020.
Changes to Canada’s Patented Medicine Prices Review Board regulations have been postponed for a fourth time in two years as Canadians continue to pay some of the highest drug prices in the world.
The level of evidence for withdrawing a drug does not appear to affect the pharma company’s response.
When drugs are taken off the market because they are either unsafe or don’t work, do pharma companies admit that there are problems? Or do they deny the evidence?
Bacteria that are resistant to every available antibiotic in the U.S. already exist.
Rodolfo Parulan Jr/Moment via Getty Images
If no action is taken to address antibiotic resistance, infections from multidrug-resistant bacteria could cause 10 million deaths each year by 2050.
Gene therapy uses our genomic makeup to treat or prevent disease.
ktsimape/iStock via Getty Images
New payment models may mean more of the people who need these treatments can get them.
The COVID pandemic is giving drug companies an opportunity to reset their image. So how did they get so big and their credibility sink so low?
The first Pfizer-BioNTech COVID-19 vaccine dose in Canada sits ready for use at The Michener Institute in Toronto in mid-December 2020, less than a year from when the World Health Organization declared COVID-19 a pandemic.
THE CANADIAN PRESS/Frank Gunn
If Big Pharma wants to achieve the ultimate image makeover, it must capitalize on the current public good will about its COVID-19 vaccines by prioritizing socially responsible practices.
Though drug recalls are relatively uncommon in the U.S., reduced inspections increase the likelihood of manufacturing errors that slip through the cracks.
AP Photo/Rafiq Maqbool
COVID-19 has exacerbated a backlog of domestic and foreign drug manufacturing inspections that the FDA is still too short-staffed to adequately deal with.
Waiver talks might convince companies to focus on technology transfer and training, and let go of the plan to maximise patent-based revenues.
Anita Anand, Canada’s minister of public services and procurement, opens a box with some of the first 500,000 of the two million AstraZeneca COVID-19 vaccine doses that Canada secured last March through a deal with the Serum Institute of India.
THE CANADIAN PRESS/Carlos Osorio - POOL
Despite some public virtue signalling, the Canadian government is not doing all it can to improve global access to COVID-19 vaccines. Canada has yet to announce its position on the WTO patent waiver.
A woman who said she’s a medical worker who works directly with COVID-19 patients is stopped by police outside of the public Rebagliati Hospital in Lima, Peru, in February 2021. She complained that some people getting vaccinated don’t work directly with COVID-19 patients.
(AP Photo/Martin Mejia)
A vaccination queue-jumping scandal in Peru has caused a massive uproar in the South American country. It could also be a wake-up call for all nations.
The average price for an orphan drug is more than $150,000 per year.
GP Kidd/Cultura/Getty Images
‘Orphan drugs’ with high price points are being tested as treatments for COVID-19. There’s a better way to spur low-cost innovation for new drugs.
A private market should have no place in the rollout of a COVID vaccine.
The funding, procurement, storage and distribution of a vaccine present huge challenges to all governments, including New Zealand’s.